Gelteq Ltd

GELS

Market cap $11.1M

MELBOURNE, Australia, June 17, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) ("Gelteq" or the "Company"), a biotechnology company developing a proprietary gel-based delivery platform for pharmaceutical, animal health and consumer health applications, today provided a corporate update on recent clinical and commercial milestones toward broader pharmaceutical adoption. Highlights Over the first half of 2026, Gelteq has commenced veterinary and pharmaceutical development programs, expanded its delivery platform, and advanced toward future clinical milestones including: Human clinical trial planning completed and the clinical trial is expected to commence next quarter (beginning July 1, 2026), which is anticipated to advance Gelteq's pharmaceutical program toward a potential FDA regulatory pathway; Veterinary clinical trial commenced for an antiparasitic drug candidate, supporting a planned FDA application targeted for later in 2026 in a global animal health market estimated to exceed US$78 billion1; Preclinical diabetes study commenced, expanding the pharmaceutical pipeline into a major chronic-disease category; Development underway in our research facilities to incorporate peptides and peptide-based therapeutics into stable oral formulations, spanning compounds traditionally delivered by injection and an emerging generation of therapies in development; Signed a strategic debt financing of up to US$3.5 million with an institutional investor to advance our clinical programs and accelerate commercialization; Veterinary palatability trials with Kemin Industries completed, demonstrating strong canine acceptance and confirming Gelteq's ability to mask bitter functional ingredients; Commercial product manufactured for a new customer in the East Asian region, demonstrating Gelteq's ability to formulate, manufacture and deliver at commercial scale; Center of Excellence established in Guangdong Province, China, providing strategic access to one of the world's fastest-growing pharmaceutical ecosystems; and Continued expansion of the active pharmaceutical ingredient (“API”) pipeline across multiple therapeutic categories.

MELBOURNE, Australia, June 12, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”) today announced the successful completion of its veterinary palatability trials conducted in collaboration with Kemin Industries (“Kemin”), a leading U.S.-based global ingredient manufacturer. The trials were designed to optimise flavour profiles and assess canine acceptance of products powered by Gelteq® technology, the Company's proprietary gel-based delivery platform.

MELBOURNE, Australia, June 04, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced the establishment of a new Gelteq Center of Excellence in Guangdong Province, China. The Gelteq Center of Excellence will serve as a strategic regional hub enabling deeper integration with and strategic access to one of the world's fastest-growing pharmaceutical and biotechnology ecosystems.

MELBOURNE, Australia, May 20, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced the commencement of its first clinical trial for an antiparasitic drug candidate powered by Gelteq® technology, marking a significant milestone as the Company expands into the veterinary pharmaceutical sector. The clinical trial seeks to support Gelteq's planned FDA regulatory pathway for animal use, with the Company targeting a potential application later in 2026.

2026 Outlook Strengthened by New Major Global Partnership with Sommer Ray's Imaraïs Beauty and Entrance into $730 Billion Health & Beauty Market LAS VEGAS, NV / ACCESS Newswire / May 14, 2026 / Healthy Extracts Inc. (OTCQB:HYEX), a leader in nutraceutical innovations and precision dose gummy manufacturing, reported record results for the first quarter ended March 31, 2026. Financial comparisons are to the same year-ago period unless otherwise noted.

MELBOURNE, Australia, May 12, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced that it has secured strategic debt financing of up to USD $3.5 million to accelerate its commercialization, expand clinical trial activity and execute on existing revenue opportunities. Gelteq intends to use the proceeds of the financing to advance its key strategic initiatives, including scaling up clinical trial programs as Gelteq advances its pharmaceutical products through regulatory pathways and ramping up commercialization of its nutraceutical products.

2025 Non-GAAP Net Income Totaled $162,000 or $0.02 Per Share Record Results Driven by Fifth Sequential Quarter of Record-Setting Revenues, with the Momentum Setting Stage for Another Year of Double-Digit Growth LAS VEGAS, NV / ACCESS Newswire / April 8, 2026 / Healthy Extracts Inc. (OTCQB:HYEX), a leader in nutraceutical innovations and precision dose gummy manufacturing, reported audited results for the year ended December 31, 2025. All comparisons are to the same year-ago period unless otherwise noted.

Strong Annual Results Driven by Record-Setting Revenues for Fifth Quarter in a Row, Setting Stage for Another Record Year in 2026   LAS VEGAS, NV / ACCESS Newswire / April 2, 2026 / Healthy Extracts Inc. (OTCQB:HYEX), a leader in nutraceutical innovations and precision dose gummy manufacturing, reported preliminary unaudited results for year ended December 31, 2025. All comparisons are to the same year-ago period unless otherwise noted.

MELBOURNE, Australia and LAS VEGAS, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) and Healthy Extracts™ Inc. (“Healthy Extracts”) today announced the signing of a Memorandum of Understanding (“MoU”) formalising a strategic partnership designed to accelerate the commercial rollout of next-generation gel-based nutraceutical products. The collaboration builds on Healthy Extracts' prior purchases of Gelteq-formulated products and marks the first phase of a long-term plan to bring Gelteq's proprietary gel delivery technology to large-scale US manufacturing and global distribution.

MELBOURNE, Australia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based developer of advanced gel-based oral delivery systems, today announced positive results from a recently completed preclinical study which evaluated medicinal cannabinoids delivery through the Company's proprietary oral gel platform. The findings demonstrate that Gelteq's platform significantly enhances the absorption and bioavailability of cannabidiol (“CBD”) compared to an existing FDA approved oil-based product. The preliminary results reinforces our platform's potential to change how medicinal cannabis is delivered and experienced by patients.